Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin McKenzie

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|December 1, 2010
In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008Jeannette Ouyang-Latimer, Syed Jafri, Audrey VanTassel, et al.
Journal of Clinical Microbiology|January 29, 2010
Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter speciesZhi-Dong Jiang, Herbert L Dupont, Eric L Brown, et al.
Plos One|March 29, 2018
Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity scoreChad K Porter, Amanda Lynen, Mark S Riddle, et al.
The Journal of Infectious Diseases|June 2, 2011
Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19Robin McKenzie, Chad K Porter, Joyce A Cantrell, et al.
Infection and Immunity|January 24, 2006
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adultsRobin McKenzie, A Louis Bourgeois, Fayette Engstrom, et al.
Plos One|March 4, 2016
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coliChad K Porter, Mark S Riddle, Ashley N Alcala, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2017
Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 StudySeema U Nayak, J McLeod Griffiss, Jeffrey Blumer, et al.
The Journal of Infectious Diseases|March 22, 2019
Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection ModelStephen J Savarino, Robin McKenzie, David R Tribble, et al.
The Journal of Infectious Diseases|May 26, 2017
Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 TrialStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Open Forum Infectious Diseases|January 9, 2019
Procalcitonin-Guided Antibiotic Therapy Reduces Antibiotic Use for Lower Respiratory Tract Infections in a United States Medical Center: Results of a Clinical TrialJennifer Townsend, Victoria Adams, Panagis Galiatsatos, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|December 1, 2010
In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008Jeannette Ouyang-Latimer, Syed Jafri, Audrey VanTassel, et al.
Journal of Clinical Microbiology|January 29, 2010
Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter speciesZhi-Dong Jiang, Herbert L Dupont, Eric L Brown, et al.
Plos One|March 29, 2018
Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity scoreChad K Porter, Amanda Lynen, Mark S Riddle, et al.
The Journal of Infectious Diseases|June 2, 2011
Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19Robin McKenzie, Chad K Porter, Joyce A Cantrell, et al.
Infection and Immunity|January 24, 2006
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adultsRobin McKenzie, A Louis Bourgeois, Fayette Engstrom, et al.
Plos One|March 4, 2016
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coliChad K Porter, Mark S Riddle, Ashley N Alcala, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2017
Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 StudySeema U Nayak, J McLeod Griffiss, Jeffrey Blumer, et al.
The Journal of Infectious Diseases|March 22, 2019
Hyperimmune Bovine Colostral Anti-CS17 Antibodies Protect Against Enterotoxigenic Escherichia coli Diarrhea in a Randomized, Doubled-Blind, Placebo-Controlled Human Infection ModelStephen J Savarino, Robin McKenzie, David R Tribble, et al.
The Journal of Infectious Diseases|May 26, 2017
Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 TrialStephen J Savarino, Robin McKenzie, David R Tribble, et al.
Open Forum Infectious Diseases|January 9, 2019
Procalcitonin-Guided Antibiotic Therapy Reduces Antibiotic Use for Lower Respiratory Tract Infections in a United States Medical Center: Results of a Clinical TrialJennifer Townsend, Victoria Adams, Panagis Galiatsatos, et al.
Pageof 4